(±) -Lisofylline-d4

• Description :

  (±) -Lisofylline-d4 ((±) -Lisophylline-d4) is deuterium labeled (±) -Lisofylline. (±) -Lisofylline ((±) -Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1].

• Product Name Alternative :

  (±) -Lisophylline-d4

• UNSPSC :

  12352005

• Target :

  Interleukin Related; Isotope-Labeled Compounds

• Related Pathways :

  Immunology/Inflammation; Others

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Inflammation/Immunology

• Smiles :

  O=C1C2=C(N=CN2C([2H])([2H])[2H])N(C(N1CCCCC(O)([2H])C)=O)C

• Molecular Formula :

  C13H16D4N4O3

• Molecular Weight :

  284.35

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Yang Z, et al. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69 (1) :1-5.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1185879-05-3]